Therapy News and Research

RSS

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

ViroPharma reports 76% growth in fourth-quarter net product sales

ViroPharma Incorporated reported today its financial results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Five Prime Therapeutics receives milestone payment for selection of therapeutic program

Five Prime Therapeutics, Inc. today announced it received a milestone payment from Centocor Research & Development, Inc. for the selection of a therapeutic that will be pursued for immunology-related indications. Under the collaboration, FivePrime identified multiple potential therapeutic targets through screening its comprehensive proprietary protein library in cell-based assays that were focused on therapeutic pathways underlying specific immune and inflammatory disorders.

24 Feb 2010

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

BioMarin Pharmaceutical Inc. today announced financial results for the fourth quarter and year ended December 31, 2009. GAAP net income was $4.7 million ($0.05 per diluted share) for the fourth quarter of 2009, compared to GAAP net income of $24.5 million ($0.21 per diluted share) for the fourth quarter of 2008, which included a $30.0 million payment from Merck Serono related to the approval of Kuvan in the EU.

24 Feb 2010

Pain-free sedation dentistry may help reduce fear of the dentist

Fear of the dentist is a huge problem in the United States. While as many as four out of five Americans admit being afraid of the dentist, it is estimated that one in seven Americans never get any dental treatment at all because of dental phobia. Sedation dentistry is a pain-free option.

24 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Osiris Therapeutics, Inc. today reported that a new study shows Prochymal achieved an overall response rate of 63% when used as a rescue therapy in children suffering from severe treatment resistant graft vs. host disease (GvHD).

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

A comparison of two strategies for treating severe sepsis or septic shock finds that using lactate levels measured in blood samples showed a similar short-term survival rate compared to a treatment regimen using central venous oxygen saturation measured using a specialized catheter, according to a study in the February 24 issue of JAMA.

24 Feb 2010

Multidisciplinary care teams can also reduce risk of dying in ICUs of hospitals without intensivists

The severe shortage of specially-trained intensivist physicians has hospital intensive care units (ICUs) nationwide struggling to staff units with critical care teams led by intensivists, even though the presence of these specially trained physicians reduces the risk of death for patients in the ICU. A new Penn Medicine report found that replacing intensivist-led teams with multidisciplinary care teams can also reduce the risk of dying in intensive care units. The study appears in the February 22 edition of the Archives of Internal Medicine.

24 Feb 2010

NJPA files lawsuit against state's health service providers for violating patient confidentiality rights

The New Jersey Psychological Association, the professional organization representing more than 2,100 psychologists who treat hundreds of thousands of people throughout the state, announced today that it filed a lawsuit against the New Jersey State Health Benefits Commission, Horizon Healthcare Services, Inc. and Magellan Health Services alleging violation of patient confidentiality rights provided by the New Jersey Practicing Psychology Licensing Act.

24 Feb 2010

More than 100 people enrolled in UK's tobacco treatment programs

Almost three months after the University of Kentucky became tobacco-free, more than 100 people are enrolled in UK's individual or group tobacco treatment programs, and more than 50 are taking advantage of UK's free nicotine replacement therapy.

24 Feb 2010

LifeSciences British Columbia, UBC to host global summit on HIV/AIDS

LifeSciences British Columbia, the BC Centre of Excellence in HIV/AIDS, and the University of British Columbia will host a global summit on HIV/AIDS on Feb. 26th, 2010, against the backdrop of the 2010 Olympic Games.

24 Feb 2010

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

PointCare Technologies, pioneer inventor of a portable diagnostic system that enables effective HIV/AIDS monitoring for millions of people in remote areas of developing countries, has donated 4,000 (a month's supply) of its rapid PointCare NOW tests to Haitian clinics to ensure the resumption of critical care to HIV/AIDS patients.

24 Feb 2010

Mouse study provides new way to test novel therapies for liver infections

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver.

24 Feb 2010

New treatments for heart disease

Two studies published in the latest issue of Cell Transplantation (18:12) may lead to new treatments for the treatment of heart diseases. The first study, carried out by a team of Brazilian researchers, found that cell transplantation of bone marrow mononuclear cells (BMMCs) directly into the heart benefited patients suffering from refractory angina.

24 Feb 2010

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

BSD Medical Corporation today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang.

24 Feb 2010

Combination therapies effective for treating depression

Even after she left her alcoholic, abusive husband behind, Patrice, a nurse in Florida, couldn't summon the energy to keep her house straight, couldn't sleep.

24 Feb 2010

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced that it has entered into a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Commerce Court Small Cap Value Fund, Ltd. over an approximately 18-month period. Poniard is not obligated to utilize any of the facility and remains free to enter into other financing transactions.

24 Feb 2010

AMT announces full year 2009 results; reports modest decrease in operating expenses

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009.

24 Feb 2010

Therapy News and Research

Shire receives FDA Fast Track designation for REPLAGAL

ViroPharma reports 76% growth in fourth-quarter net product sales

Five Prime Therapeutics receives milestone payment for selection of therapeutic program

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

Pain-free sedation dentistry may help reduce fear of the dentist

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

Multidisciplinary care teams can also reduce risk of dying in ICUs of hospitals without intensivists

NJPA files lawsuit against state's health service providers for violating patient confidentiality rights

More than 100 people enrolled in UK's tobacco treatment programs

LifeSciences British Columbia, UBC to host global summit on HIV/AIDS

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

Mouse study provides new way to test novel therapies for liver infections

New treatments for heart disease

BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

Combination therapies effective for treating depression

Poniard Pharmaceuticals enters into $20M committed equity financing facility with Commerce Court Small Cap Value Fund

AMT announces full year 2009 results; reports modest decrease in operating expenses

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News